Lanfos Chewable Tablet
Lanthanum Carbonate
250mg
Beacon Pharmaceuticals Ltd.
| Pack size | 30's Pack |
|---|---|
| Unite Price | 80.00 BDT |
Indications
Lanfos Chewable Tablet is used for:
Hyperphosphataemia in patients with chronic renal failure
Adult Dose
Oral
Hyperphosphataemia in patients with chronic renal failure
Adult: As chewable tab/oral powd: Initially, 0.75-2.25 g daily in 3 divided doses.
Maintenance dose: 1.5-3 g daily in divided doses.
Max: 3.75 g daily.
Dose is adjusted every 2-3 wk according to serum phosphate level.
Child Dose
Renal Dose
Administration
Should be taken with food. Take w/ or immediately after meals.
Contra Indications
Bowel obstruction, ileus, faecal impaction, hyperphosphataemia.
Precautions
Patient w/ altered GI anatomy (e.g. diverticular disease, peritonitis, history of GI surgery, GI cancer, GI ulceration), hypomotility disorders (e.g. constipation, diabetic gastroparesis), active peptic ulcer, Crohn's disease, ulcerative colitis. Hepatic impairment. Pregnancy and lactation. Patient Counselling This drug may cause dizziness and vertigo, if affected, do not drive or operate machinery. Monitoring Parameters Monitor serum Ca, phosphorus levels.
Pregnancy-Lactation
Pregnancy
Available data from case reports in pregnant women are insufficient to identify a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes; use a non-lanthanum containing phosphate binder in a pregnant woman
Animal data
In animal reproduction studies, oral administration to pregnant rats and rabbits during organogenesis at doses 3 and 2.5 times, respectively, the maximum recommended human dose (MRHD), resulted in no adverse developmental effects
In rabbits, lanthanum carbonate doses 5 times the MRHD was associated with maternal toxicity and resulted in increased post-implantation loss, reduced fetal weights, and delayed fetal ossification
Deposition of lanthanum into developing bone, including growth plate, was observed in juvenile animals in long-term animal studies with lanthanum carbonate
Lactation
There are no data on presence of drug in human milk, effects on breastfed infant, or on milk production; deposition of lanthanum into developing bone, including growth plate, was observed in juvenile animals in long-term animal studies with lanthanum carbonate; use a non-lanthanum containing phosphate binder in a lactating woman
Interactions
May reduce bioavailability of quinolones, tetracycline and levothyroxine chloroquine, ketoconazole. May decrease serum concentration of ACE inhibitor, ampicillin, halofantrine.
Side Effects
Side effects of Lanthanum Carbonate :
1-10%
Abdominal pain
Constipation
Dialysis graft complication/occlusion
Diarrhea
Headache
Hypertension
Nausea
Vomiting
<1%
Bronchitis
Hypercalcemia
Rhinitis
Mode of Action
Lanthanum carbonate is a phosphate binder which inhibits the absorption of dietary phosphate from the intestines. It disintegrates in the GI tract to lanthanum ions (La 3+) that binds phosphate to make insoluble and unabsorbable lanthanum phosphate complexes, causing a decrease in serum phosphate and Ca levels.
Note
Lanfos 250mg Chewable Tablet generic name is Lanthanum Carbonate. Lanfos 250mg Chewable Tablet is manufactured by Beacon Pharmaceuticals Ltd.Lanfos is availble in all over Bangladesh.
Mes BD drug index information on Lanfos Chewable Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.